Biotech as a Strategic Asset: Dr. Jeremy Levin on Science, Policy, and Public Trust

Biotechnology has helped transform what is possible in medicine, turning once-fatal diseases into manageable conditions and opening the door to treatments that would have seemed impossible a generation ago. But as science advances, the systems that support innovation are under pressure, from public trust and policy decisions to capital formation, regulation, and confidence in scientific institutions.In this episode of Russo Edge, Dr. Jeremy Levin, co-founder and executive chairman of Ovid Therapeutics, former CEO of Teva, former chair of BIO, and a longtime biopharma leader whose career has included senior roles at Bristol Myers Squibb and Novartis, joins host Solomon Wilcots for a conversation on why biotech should be viewed as one of America’s most important strategic assets.The conversation also explores the difference between biotech innovators and larger pharmaceutical companies, the complexity of drug pricing, the role of middlemen in the healthcare system, and why the public often does not see the full story behind how medicines are discovered, developed, funded, and delivered.Whether you are a biotech leader, investor, policymaker, or simply interested in the future of medicine, this episode offers a timely look at the pressures facing the industry and the choices that will shape what comes next.